Vascular endothelial growth factor as a potential prognostic factor for T3N0 rectal cancer

Aleksandar Sekulić; Goran Barišić; Duško Dundjerović; Svetislav Tatić; Zoran Krivokapić

doi:10.2298/VSP180120071S

Aleksandar Sekulić Clinical Centre of Serbia, First Surgical Clinic, Clinic for Digestive Surgery, Belgrade, Serbia
Goran Barišić Clinical Centre of Serbia, First Surgical Clinic, *Clinic for Digestive Surgery, Belgrade, Serbia
Duško Dundjerović University of Belgrade, Institute of Pathology, Belgrade, Serbia
Svetislav Tatić University of Belgrade, Institute of Pathology, Belgrade, Serbia
Zoran Krivokapić Clinical Centre of Serbia, First Surgical Clinic, Clinic for Digestive Surgery, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP180120071S

Keywords: biomarkers, prognosis, rectal neoplasms, recurrence, vascular endothelial growth factor

Abstract

Background/Aim. Rectal cancer still presents a major health problem. Although a surgery is the mainstay of the rectal cancer treatment, there is now widespread agreement that combined modality therapy is often indicated. Around 20% of T3N0 rectal cancer patients develop distant or local relapse of the disease. There is a need for prognostic biomarkers that could help us determine the subgroup of patients with a high risk for recurrence. The aim of this study was to determine the prognostic potential of vascular endothelial growth factor (VEGF) in patients with T3N0 rectal carcinoma. Methods. This retrospective study included 163 selected T3N0 rectal cancer patients, operated on the Department for Colorectal Surgery of the Clinic for Digestive Surger (First Surgical Clinic), Clinical Centre of Serbia, Belgrade. VEGF expression was immunohistochemically assessed. Oncological outcome was analyzed using data from prospectively designed data base. Parameters of interest were: distant metastases, the disease free and overall survival. Survival and time to recurrence were evaluated using Kaplan Meier`s method and the factors were compared with the long-rank test. Results. There were 102 men and 61 women. The median age was 62 years (age range, 31–88 years). Median follow-up interval was 81 months (range, 4–177 months). During the follow-up period 6 patients developed local recurrence, in 31 patients distant metastases occurred. Three factors were found to be associated with distant metastases: VEGF expression, mucinous adenocarcinoma and tumor differentiation (p < 0.05). In patients with positive VEGF expression, the disease free survival and overall survival were significantly worse than in negative ones (65% and 59%, respectively) (log-rank test, p < 0.05). Conclusion. High VEGF expression in T3N0 rectal carcinomas together with some standard histopathological tumor features can give us enough information to identify subgroup of patients with high risk for recurrence and poorer prognosis.

References

Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28(Suppl 4): iv22–iv40.

Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, et al. Efficacy endpoints of radiation therapy group proto-col 0247: A randomized, phase 2 study of neoadjuvant radia-tion therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015; 91(1): 116–23.

Song JH, Jeong JU, Lee JH, Kim SH, Cho HM, Um JW, et al. Preoperative chemoradiotherapy versus postoperative chemo-radiotherapy for stage II-III resectable rectal cancer: A meta-analysis of randomized controlled trials. Radiat Oncol J 2017; 35(3): 198–207.

Mejri N, Dridi M, Labidi S, El Benna H, Daoud N, Boussen H. Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy. Clin Transl Oncol 2017; 19(12): 1524–30.

Nissan A, Stojadinovic A, Shia J, Hoos A, Guillem JG, Klimstra D, et al. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Oncol 2006; 24(25): 4078–84.

Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular biomarkers for the evaluation of colorectal cancer: Guideline summary from the American society for clinical pathology, college of Ameri-can pathologists, association for molecular pathology, and American society of clinical oncology. J Oncol Pract 2017; 13(5): 1453–86.

Kim JW, Kim YB, Choi JJ, Koom WS, Kim H, Kim NK, et al. Molecular markers predict distant metastases after adjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2012; 84(5): e577–84.

Van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Dutch Colorectal Cancer Group. Preoper-ative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multi-centre, randomised controlled TME trial. Lancet Oncol 2011; 12(6): 575–82.

Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, et al. The angiogenic switch for vascular endo-thelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorec-tal cancer progression. J Pathol 2003; 200(2): 183–94.

Martins SF, Garcia EA, Luz MAM, Pardal F, Rodrigues M, Filho AL. Clinicopathological correlation and prognostic signifi-cance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 ex-pression in Colorectal cancer. Cancer Genomics Proteomics 2013; 10(2): 55–67.

Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with to-tal mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345(9): 638–46.

Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery”the clue to pelvic recurrence? Br J Surg 1982; 69(10): 613–6.

Kulu Y, Tarantino I, Billeter AT, Diener MK, Schmidt T, Büchler MW, et al. Comparative Outcomes of Neoadjuvant Treat-ment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer. Ann Surg Oncol 2016; 23(1): 106–13.

Glimelius B, Grönberg H, Järhult J, Wallgren A, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003; 42(5–6): 476–92.

Taylor FG, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-Year follow-up results of the MER-CURY Study. J Clin Oncol 2014; 32(1): 34–43.

Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. Esmo consensus guidelines for manage-ment of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23(10): 2479–516.

Nikberg M, Chabok A, Letocha H, Kindler C, Glimelius B, Smedh K. Lymphovascular and perineural invasion in stage II rectal cancer: a report from the Swedish colorectal cancer registry. Acta Oncol 2016; 55(12): 1418–24.

Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006; 94(12): 1823–32.

Wang Y, Yao X, Ge J, Hu F, Zhao Y. Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and me-ta-analysis. ScientificWorldJournal 2014; 2014: 102736.

Gunther K, Dworak O, Remke S, Pfluger R, Merkel S, Hohenberger W, et al. Prediction of distant metastases after curative surgery for rectal cancer. J Surg Res 2002; 103(1): 68–78.

Whittaker MA, Carr NJ, Midwinter MJ, Badham DP, Higgins B. Acinar morphology in colorectal cancer is associated with sur-vival but is not an independent prognostic variable. Histo-pathology 2000; 36(5): 439–42.

Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A, Kombouras C. Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res 2008; 147(1): 99–107.

Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000; 6(7): 2803–7.

Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, et al. Vessel counts and expression of vascular en-dothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132(5): 541–6.